Entering text into the input field will update the search result below

Sarepta shares up as FDA approves AMONDYS 45 for Duchenne Muscular Dystrophy

  • The FDA has approved AMONDYS 45 (casimersen) from Sarepta Therapeutics (NASDAQ:SRPT) for the treatment of Duchenne Muscular Dystrophy in patients that have a mutation amendable to exon 45 skipping.
  • Commercial distribution will begin immediately.
  • Sarepta will continue the placebo-controlled ESSENCE

Recommended For You

About SRPT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SRPT--
Sarepta Therapeutics, Inc.